CalciMedica Inc. (CALC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CalciMedica Inc. (CALC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Gainers
Pharvaris (NASDAQ:PHVS) stock moved upwards by 19.4% to $36.9 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.0 billion.
CalciMedica (NASDAQ:CALC) shares roseread more...
CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential...
Gainers
Autonomix Medical (NASDAQ:AMIX) stock rose 49.1% to $4.1 during Tuesday's after-market session. The market value of their outstanding shares is at $1.5 million.
CalciMedica (NASDAQ:CALC) shares rose 9.8%read more...
CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program PR Newswire LA JOLLA, Calif., June 24, 2026...
CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data PR Newswire LA JOLLA, Calif., June 24, 2026 FDA...
CalciMedica said that it has decided to discontinue the trial evaluating its lead product candidate Auxora in patients with Stage 2 or Stage 3 acute kidney injury following a committee recommendation.